The Effect of the Iranian Surfactant (Beraksurf) in the Treatment of Respiratory Distress Syndrome in Premature Neonates

Abstract

Background: Respiratory distress syndrome (RDS) is a type of lung development defect that is commonly seen in preterm births. Deficiency of pulmonary surfactant due to immaturity is the principal cause of RDS in premature infants. This study was conducted with the aim of Iranian surfactant (Beraksurf)’s effect in treating RDS in premature neonates.
 Methods: In this study, all infants who were premature and had RDS were included in the study. Also, the infants were examined based on primary and secondary outcomes. Primary outcomes include the duration of need for nasal continuous positive airway pressure (NCPAP), number of surfactant administration, and secondary outcomes including bronchopulmonary dysplasia (BPD), pneumothorax, and pulmonary hemorrhage.
 Results: A total of 162 neonates with a mean gestational age of 31.28 ± 2.58 weeks were evaluated. The 120 people (74.1%) used medicine only on the first day, 19 people on other days, and 23 people on the first and second day. Also, 141 children (87.6%) were discharged from the hospital and unfortunately, 20 children (12.4%) died. The prevalence of pneumothorax, BPD, and pulmonary hemorrhage was 1.8%, 1.2%, and 1.2% respectively. Also, 69.7% needed less than five days of mechanical ventilation and 30.2% needed more than 5 days of mechanical ventilation.
 Conclusion: Considering getting better treatment results from taking Beraksurf, as well as fewer side effects and the fact that this drug is Iranian, and due to its easier access and cheaper price, we can pay more attention to the prescription of this drug.